Know Cancer

forgot password

Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

18 Years
Open (Enrolling)
Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms

Thank you

Trial Information

Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

This is a blood serum collection study at Stanford University for patients with cancer at a
variety of disease sites. The purpose of this study is to collect and store blood serum
from patients before, during, and after anti-cancer therapy to find new biomarkers that
signal disease or response to anti-cancer therapy. The collection and analysis of these
biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in
the future. We are also interested in collecting blood serum from healthy individuals such
as the spouses, relatives, and friends of cancer patients to obtain healthy controls for

Inclusion Criteria:

- Over age 18, no maximum age limit

- Prior diagnosis of cancer (unless healthy control)

- Karnofsky performance status of greater than 70

- Standard pre-treatment evaluation

- Negative pregnancy test

- Signed informed consent

Exclusion Criteria:- Less than 18 years old

- Patient without cancer (unless healthy control)

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Survival analysis and response to anti-cancer therapy

Outcome Time Frame:

At each follow-up (3 months, 6 months, 1 year; at discretion of MD) 2- Safety Issue?- No

Safety Issue:


Principal Investigator

Albert Koong

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University


United States: Institutional Review Board

Study ID:




Start Date:

January 2002

Completion Date:

Related Keywords:

  • Carcinomas (Including Squamous Cell and Adenocarcinoma)
  • Neoplasms
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Neoplasms
  • Carcinoma



Stanford University School of Medicine Stanford, California  94305-5317